Some diseases advance hidden, without warning or striking hard. Pancreatic cancer embodies this discreet threat, often detected too late to allow effective treatment. Faced with this failure of early diagnosis, a path long considered marginal is now gaining credibility. A breath test for cancer could deliver, in one breath, what years of research had failed to guarantee.
Why pancreatic cancer often goes unnoticed
Every year, pancreatic cancer slips off the medical radar until it's too late. The cause is misleading symptoms, often reduced to simple back pain, digestive problems or fatigue. This clinical vagueness delays diagnoses and makes treatments less effective.
Figures published by The Independent show that 62% of patients in England are diagnosed at stage 4. In Wales this proportion rises to 65%. At this point in the journey, almost a quarter do not survive beyond a month. Such statistical brutality is explained, in part, by the absence of a reliable and accessible tool to detect the disease before serious signs.
Today, people suspected of having pancreatic cancer undergo extensive examinations, such as imaging or biopsies. Unfortunately, these tests often come too late. The need for a change in early detection therefore becomes evident. It is in this context that a unique project begins to arouse interest.
A breath test for cancer based on the chemistry of exhaled air
What if the air we exhale revealed the presence of an as yet undetectable tumor? Long considered too daring, this idea is now guiding a pilot project led by Imperial College London, in collaboration with the Pancreatic Cancer UK association.
The principle is simple in appearance: analyze the volatile organic compounds (or VOCs) present in human breath. These molecules, produced by the body's cells, circulate in the blood before being eliminated by the lungs. Their combination varies depending on the state of health, and certain chemical signatures would be typical of cancers, even at a very early stage.
A first trial, carried out on 700 patients over two years, gave results considered promising. Today, a large-scale clinical trial is underway involving 6,000 people at 40 sites across England, Scotland and Wales. This is the first breath test dedicated to pancreatic cancer to reach such a level of clinical evaluation.
According to the Good News Network, this device could detect signs of the disease well before it manifests clinically, with results available in just three days. If the performance is confirmed, this tool could be integrated into general practitioner consultations in the years to come.
How this technology changes for patients and doctors
The challenge goes far beyond technical innovation alone. This test paves the way for a faster, simpler and more accessible approach to screening. A patient suffering from abdominal pain could, at the first appointment, blow into a device and receive clear guidance, without waiting weeks.
For caregivers, the benefits would be just as clear. This test would help them identify high-risk patients earlier. They could thus avoid unnecessary examinations for others and offer treatment in time, when the disease is still controllable.
Diana Jupp, head of Pancreatic Cancer UK, sees this innovation as a beacon of hope for patients. The association is strongly committed since it is investing more than a million pounds in the clinical trial. For his part, Professor George Hanna, at Imperial College London, believes that this method could transform the organization of care pathways. Ultimately, the objective remains unchanged. Integrate this technology into current medical practices.
Without making any premature promises, the first results suggest a decisive breakthrough. The history of cancer screening could well be written, in part, from a single breath.
With an unwavering passion for local news, Christopher leads our editorial team with integrity and dedication. With over 20 years’ experience, he is the backbone of Wouldsayso, ensuring that we stay true to our mission to inform.
